RxDoctor Payments Data

Salimah Cumber, MD

Family Medicine · Houston, TXNPI 1912011966

Payments from drug & device makers

$4,860in general payments, 2019–2025

Across 300 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$2K
  • AstraZeneca$913
  • Pfizer$715
  • AbbVie$432
  • GSK$212
  • Lilly USA, LLC$123
  • plus $295 from 10 others

What the payments were for

  • Food & beverage$4,82899%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,860 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$49,180
Medicare patients
115
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$158,140
JardianceEmpagliflozin88$135,773
MounjaroTirzepatide67$93,924
JanuviaSitagliptin Phosphate53$85,095
FarxigaDapagliflozin Propanediol56$69,818
EliquisApixaban46$62,259
VascepaIcosapent Ethyl57$51,220
TradjentaLinagliptin27$41,978
XareltoRivaroxaban30$37,970
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$35,950
TrulicityDulaglutide18$31,753
LinzessLinaclotide24$30,841
MyrbetriqMirabegron23$24,282
EntrestoSacubitril/Valsartan12$17,685
Tresiba Flextouch U-100Insulin Degludec16$11,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$75$158,140114 claims
Lilly USA, LLCMounjaro, Trulicity$123$125,67785 claims
MerckJanuvia$16$85,09553 claims
AstraZenecaFarxiga, Symbicort$913$74,81571 claims
PfizerEliquis$715$62,25946 claims
GSKTrelegy Ellipta, Breo Ellipta$212$41,22060 claims
Johnson & JohnsonXarelto$37$37,97030 claims
AbbVieLinzess$432$30,84124 claims
NovartisEntresto$18$17,68512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →